美國OCT鎮痛劑市場

Abstract

The over-the-counter internal analgesic market is projected to nearly $3 billion in 2007. Shifting age demographics are helping the market, but growth has been sidetracked by controversial safety concerns. Brand marketers spend millions each year to launch brand extensions and delivery forms, but can new demand really be spurred in this mature market?

Mintel provides detailed analysis and insights, including consumer research commissioned especially for this report. Topics include:

• The impact of recent safety concerns on sales volume
• Why consumers limit their usage of pain relievers
• Why private label share is growing and how name brands can defend themselves
• How drugstores have increased their share of FDM sales
• Which maladies draw the highest percentage of consumers to OTC pain relief products
• Perceived differences among analgesic brands
• Where consumers go for information about OTC pain relievers

For the purposes of this report, the analgesics market is defined as including all oral analgesics, which are available over the counter without a prescription. Products intended for arthritis or migraine relief, and combination sleep aid/pain relief products, are also included. Products for children are covered, though they are not the main focus of this report.

Cold, cough and allergy remedies are excluded from this report, as are alertness aids and topical analgesics.

This report contains US IRI InfoScan data.

Table of Contents

• Scope and Themes
• What you need to know
• Definition
• Survey and forecast methodology
• Abbreviations and terms
• Abbreviations
• Terms
• Executive Summary
• FDM OTC analgesics market stagnant
• Aging nation to increase volume of sales by 1.35% annually through 2012
• External analgesics encroaching on sales
• Analgesic tablets dominate market but liquids growing fastest
• Leading brand Tylenol wins for most convincing marketing
• OTC marketing focused on older consumers and young mothers
• Drug stores are the primary destination for purchase
• Negative perception limits usage, especially among under-45s
• Store brands becoming more sophisticated
• Online advertising on the rise
• Minorities more likely to avoid store brands
• Under-55s more interested in newer product formats
• Potential for ' alert and pain-free' combination products
• From products to solutions
• Market Drivers
• An aging population
  • Figure 1: U.S. population, by age, 2002-12
  • Figure 2: Incidence of pain-inducing ailments, by age, January-October 2006
• New products for an aging population
  • Figure 3: Bayer Aleve arthritis relief tablets, 2007
  • Figure 4: CVS arthritis pain relief caplets, 2007
• Anti-inflammation marketing lagging
• Sugar-free chewables for diabetics
  • Figure 5: Bayer sugar free chewable aspirin, 2007
• Shifting from prescription to OTC
  • Figure 6: OTC analgesic usage and types of pain, 2002-06
• Fear of medication
• Fear of medications grows on medical research and advisories
• New ibuprofen sleep aid
• External analgesics
  • Figure 7: FDM sales of external analgesics, at current and constant prices, 2002-07
  • Figure 8: Origin BioMedicinals Neuragen RL Nerve Pain Relief, 2007
  • Figure 9: NaturalCare Joint Health Capsules, 2007
  • Figure 10: Arkopharma Relief for Migraines, 2007
• Market Size and Trends
• Market size
  • Figure 11: Total U.S. retail sales of OTC internal analgesics, at current and constant prices, 2002-07
• Trends
• Increasing share of private label
  • Figure 12: FDM sales of private label OTC analgesics, at current and constant prices, 2002-07
  • Figure 13: Trader Joe' s Trader Darwin' s Ibuprofen, 2007
• Targeting specific indications
  • Figure 14: Excedrin Back & Body extra strength pain reliever, 2007
  • Figure 15: Extra Strength Doan' s Pain Reliever, 2007
  • Figure 16: Excedrin migraine pain relief, 2007
  • Figure 17: Equate headache relief, 2007
• Preventing stomach irritation
  • Figure 18: CVS Pharmacy enteric aspirin, 2007
  • Figure 19: GlaxoSmithKline Ecotrin, 2007
• Market Segmentation
  • Figure 20: FDM sales of OTC internal analgesics, segmented by type, 2005 and 2007
  • Figure 21: Graph: FDM sales of OTC internal analgesics, by type, 2007
  • Figure 22: Graph: Indexed FDM sales of OTC internal analgesics, by type, 2002-07
• Analgesic tablets
  • Figure 23: FDM sales of OTC analgesic tablets, at current and constant prices, 2002-07
• Analgesic liquids
  • Figure 24: FDM sales of OTC analgesic liquids, at current and constant prices, 2002-07
• Feminine pain relievers
  • Figure 25: FDM sales of OTC feminine pain relievers, at current and constant prices, 2002-07
• Supply Structure
• Introduction
• Companies and brands
  • Figure 26: FDM sales of OTC internal analgesics in the U.S., 2004 and 2006
  • Figure 27: Available physical forms of major OTC analgesic brands, 2007
  • Figure 28: Available physical forms of major OTC analgesic brands, 2007
• Analgesic tablets
  • Figure 29: FDM brand sales of analgesic tablets in the U.S., 2004 and 2006
• Analgesic liquids
  • Figure 30: FDM brand sales of analgesic liquids in the U.S., 2004 and 2006
• Feminine pain relievers
  • Figure 31: FDM brand sales of feminine pain relievers in the U.S., 2004 and 2006
• Advertising and Promotion
• Introduction
• McNeil Consumer Products
  • Figure 32: Media expenditures for Tylenol, 2005 and 2006
• Tylenol
  • Figure 33: Tylenol Arthritis Pain
  • Figure 34: Tylenol Go Tabs (October 2006)
  • Figure 35: Tylenol Promise (May 2007)
• Motrin
  • Figure 36: Motrin IB and Children' s Motrin
• Wyeth Consumer Healthcare
  • Figure 37: Media expenditures for Advil, 2005 and 2006
• Advil
  • Figure 38: Advil PM (May 2007)
  • Figure 39: Advil All Purpose (August 2007)
• Bayer Consumer Health
  • Figure 40: Media expenditures for Bayer and Aleve, 2005 and 2006
• Aleve
  • Figure 41: Aleve Over-50 Dancer (July 2007)
  • Figure 42: Aleve Liquid Gels (August 2007)
• Bayer Aspirin
  • Figure 43: Bayer Cardiac Care Unit (July 2007)
• Novartis Consumer Health
  • Figure 44: Media expenditures for Excedrin, 2005 and 2006
• Excedrin
  • Figure 45: Excedrin Headache Storm (September 2006)
  • Figure 46: Excedrin Roller Coaster (July 2007)
  • Figure 47: Excedrin Double Play (July 2007)
• Retail Distribution
• Introduction
  • Figure 48: U.S. retail sales* of OTC internal analgesics, by channel, 2005 and 2007
  • Figure 49: Average price per unit of OTC analgesics at FDM, by type, 2006
• Drug stores
  • Figure 50: U.S. drug store sales of OTC internal analgesics, at current and constant prices, 2002-07
• Supermarkets
  • Figure 51: U.S. supermarket sales of OTC internal analgesics, at current and constant prices, 2002-07
• Mass merchandisers
  • Figure 52: U.S. mass merchandiser sales* of OTC internal analgesics, at current and constant prices, 2002-07
• The Consumer: Product Usage
• Summary
• Usage
• Indications
• Usage of headache/pain relievers
  • Figure 53: Usage of headache/pain relievers, by gender, January-October 2006
  • Figure 54: Usage of headache/pain relievers, by age, January-October 2006
  • Figure 55: Usage of headache/pain relievers, by household income, January-October 2006
• Prevalence of types of pain
  • Figure 56: Prevalence of types of pain, October 2007
  • Figure 57: Prevalence of types of pain, by gender, October 2007
• OTC usage for specific pain types
  • Figure 58: OTC analgesic usage for specific types of pain, January-October 2006
  • Figure 59: OTC analgesic usage for specific types of pain, 2002-06
• Pain from menstruation
  • Figure 60: Pain from menstruation, by age, October 2007
• Indications for OTC pain relief
  • Figure 61: Indications for OTC pain relief, January-October 2006
  • Figure 62: Indications for OTC pain relief, by gender, January-October 2006
  • Figure 63: Indications for OTC pain relief, by age, January-October 2006
  • Figure 64: Sole indications for OTC pain relief, January-October 2006
• Children and OTC pain medication
  • Figure 65: Children and OTC pain medications, by gender, October 2007
  • Figure 66: Children and OTC pain medications, by age, October 2007
• Forms of OTC analgesics
  • Figure 67: Forms of OTC analgesics, by age, January-October 2006
• Race/ethnicity
  • Figure 68: Usage of headache/pain relievers, by race/ethnicity, January-October 2006
  • Figure 69: Indications for OTC pain relief, by race/ethnicity, January-October 2006
• The Consumer: OTC Brands
• Summary
• Brand observations
• Store brands
• Popularity of OTC brands
  • Figure 70: Popularity of OTC analgesic brands, January-October 2006
  • Figure 71: Popularity of OTC analgesic brands, by age, January-October 2006
  • Figure 72: Popularity of OTC analgesic brands, by household income, January-October 2006
  • Figure 73: Popularity of OTC analgesic brands, by race/ethnicity, January-October 2006
• Brands and specific actions
  • Figure 74: Brands and specific actions, October 2007
• Frequency of use by brand
  • Figure 75: Frequency of use, by brand, October 2007
• Attitudes Towards OTC Products
• Summary
• Consumer attitudes
• Sources of information
• Attitudes toward OTC pain medication
  • Figure 76: Attitudes toward OTC pain medication, October 2007
  • Figure 77: Attitudes toward OTC pain medication, by gender, October 2007
  • Figure 78: Attitudes toward OTC pain medication, by race/ethnicity, October 2007
• Reasons to limit usage
  • Figure 79: Reasons to limit usage, October 2007
  • Figure 80: Reasons to limit usage, by age, October 2007
• Attitudes toward enhanced drug action
  • Figure 81: Attitudes toward enhanced drug action, October 2007
  • Figure 82: Attitudes toward enhanced drug action, by gender, October 2007
  • Figure 83: Attitudes toward enhanced drug action, by age, October 2007
• Sources of information
  • Figure 84: Sources of information, by gender, October 2007
  • Figure 85: Sources of information, by age, October 2007
  • Figure 86: Sources of information, by presence of children in household, October 2007
• Future and Forecast
• Future trends
• Homeopathic remedies on the rise
  • Figure 87: Hyland' s BackAche with Arnica Homeopathic tablets, 2007
• Advertising shifts from consumer to patient, and from push to online
• Solutions, not products
• Vast arena for expansion in combination products as yet untapped
• Catering to the aging Boomer
• Easy to swallow
• New pharmaceutical stops menstruation
• Market forecast
• OTC analgesics market
  • Figure 88: Forecast of total U.S. retail sales of OTC internal analgesics, at current and constant prices, 2007-12
• Private label OTC analgesics
  • Figure 89: Forecast of U.S. FDM sales of private label OTC analgesics, at current and constant prices, 2007-12
• Analgesic tablets
  • Figure 90: Forecast of U.S. FDM sales of OTC analgesic tablets, at current and constant prices, 2007-12
• Analgesic liquids
  • Figure 91: Forecast of U.S. FDM sales of OTC analgesic liquids, at current and constant prices, 2007-12
• Feminine pain relievers
  • Figure 92: Forecast of U.S. FDM sales of OTC feminine pain relievers, at current and constant prices, 2007-12
• Forecast factors
• Appendix: Trade Associations